Metaclazepam
From Wikipedia, the free encyclopedia
Metaclazepam
|
|
Systematic (IUPAC) name | |
7-bromo-5-(2-chlorophenyl)-2-(methoxymethyl) -1-methyl-2,3-dihydro-1,4-benzodiazepine | |
Identifiers | |
CAS number | |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | C18H18BrClN2O |
Mol. mass | 393.705 |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Metaclazepam (Talis) is a drug which is a benzodiazepine derivative. It is a relatively selective anxiolytic with less sedative or muscle relaxant properties than other benzodiazepines such as diazepam or bromazepam.[1]
Metaclazepam is slightly more effective as an anxiolytic than bromazepam,[2] or diazepam,[3] with a 15mg dose of metaclazepam equivalent to 4mg of bromazepam.[4]
[edit] References
- ^ Buschmann G, Kuhl UG, Rohte O. General pharmacology of the anxiolytic compound metaclazepam in comparison to other benzodiazepines. Arzneimittelforschung. 1985;35(11):1643-55.
- ^ Bilone F, Roncari R. A double-blind comparison of the anxiolytic activity of two benzodiazepines, metaclazepam and bromazepam, in anxiety neurosis. Current Medical Research and Opinion. 1988;11(1):45-7.
- ^ Laakmann G, Blaschke D, Hippius H, Schewe S. Double-blind study of metaclazepam versus diazepam treatment of outpatients with anxiety syndrome. Pharmacopsychiatry. 1989 May;22(3):120-5.
- ^ Marano P, Patti F, Nicoletti F. Controlled study on the anxiolytic activity of a newly-developed benzodiazepine, metaclazepam. Current Medical Research and Opinion. 1988;11(1):41-4.
|